Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SOCS1
REST API REST API
Homo sapiens
SOCS1 is differentially expressed in 303 experiments: 123 organism parts: lung, ovary, ... (121 more);, 172 disease states: normal, Burkitt's lymphoma, ... (170 more);, 91 cell types 368 cell lines 48 compound treatments and 80 other conditions.
Synonyms SSI-1, SOCS-1, TIP3, JAB, Cish1
Orthologs Q4H2S6_CIOIN (Ciona intestinalis)   B6RCQ2_CHICK (Gallus gallus)   socs1 (Danio rerio)   SOCS1 (Bos taurus)   Socs1 (Mus musculus)   Socs1 (Rattus norvegicus)   socs1 (Xenopus laevis)   SOCS1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, insulin-like growth factor receptor binding, negative regulation of JAK-STAT cascade, protein binding, cytokine-mediated signaling pathway, cytoplasm, protein kinase binding, negative regulation of catalytic activity, response to lipopolysaccharide, response to drug, JAK-STAT cascade, negative regulation of insulin receptor signaling pathway, regulation of growth, response to cytokine stimulus, regulation of interferon-gamma-mediated signaling pathway, regulation of type I interferon-mediated signaling pathway, response to progesterone stimulus, protein kinase inhibitor activity, fat cell differentiation, organ regeneration, response to peptide hormone stimulus, response to estradiol stimulus, kinase inhibitor activity, negative regulation of tyrosine phosphorylation of Stat3 protein, regulation of protein phosphorylation, intracellular signal transduction, interferon-gamma-mediated signaling pathway, type I interferon-mediated signaling pathway, cellular response to amino acid stimulus
InterPro Term SH2, SOCS_C
UniProt Accession O15524, Q4JHT5
Search EB-eye ENSG00000185338
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
MCF7
2
E-MTAB-37, E-GEOD-5258
HepG2
2
E-MTAB-37, E-GEOD-7307
Jurkat
2
E-MEXP-2197, E-GEOD-1880
SR
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
362 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-360, ... (47 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
fibroblast
2
E-GEOD-3920, E-GEOD-3204
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-5099, E-GEOD-360, E-GEOD-8286
monocyte-derived intermediate cell
1
E-MEXP-2019
spheroid recovery
1
E-GEOD-4219
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-GEOD-16363, E-GEOD-5370, E-MTAB-680, ... (52 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
Raji Burkitt's lymphoma
2
E-AFMX-5, E-TABM-145
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
166 more value(s).


Compound treatment

studied in E-GEOD-5542, E-GEOD-1417, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (32 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-3284, E-GEOD-5339, E-GEOD-4006
interferon-gamma
3
E-GEOD-1432, E-GEOD-1925, E-GEOD-5542
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
endotoxin
1
E-GEOD-2322
camptothecin
1
E-GEOD-1417
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
42 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

Disease staging
studied in E-MEXP-480, E-TABM-147, E-GEOD-21138, E-GEOD-21887

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-20847, E-MTAB-108

Genotype
studied in E-MEXP-1996, E-GEOD-17476, E-TABM-868, E-GEOD-20115, E-TABM-601, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-7011, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (26 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, ... (6 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.512 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM